Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence

References

• ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA20032892560257212748199
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupTight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38Br Med J19983177037139732337
   PubMed Web of Science ®Google Scholar
• HanssonLZanchettiACarruthersSGEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study GroupLancet1998351175517629635947
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet20043632022203115207952
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med200134585186011565517
   PubMed Web of Science ®Google Scholar
• EstacioROSchrierRWAntihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trialAm J Cardiol19982R114
   Google Scholar
• LazarusJMBourgoignieJJBuckalewVMAchievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study GroupHypertension1997296416509040451
   PubMed Web of Science ®Google Scholar
• AgodoaLYAppelLBakrisGLEffect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trialJAMA20012852719272811386927
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakAThe task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)Eur Heart J2007281462153617562668
   PubMed Web of Science ®Google Scholar
• MatersonBJRedaDJCushmanWCDepartment of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive AgentsAm J Hypertens199581891927755948
   PubMed Web of Science ®Google Scholar
• MorganTOAndersonAIMacInnisRJACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertensionAm J Hypertens20011424124711281235
   PubMed Web of Science ®Google Scholar
• DickersonJEHingoraniADAshbyMJPalmerCRBrownMJOptimisation of antihypertensive treatment by crossover rotation of four major classesLancet19993532008201310376615
   PubMed Web of Science ®Google Scholar
• HanssonLZanchettiACarruthersSGEffects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialLancet1998351175517629635947
   PubMed Web of Science ®Google Scholar
• BarriosVEscobarCEcharriRFixed combinations in the management of hypertension: perspectives on lercanidipine – enalaprilVasc Health Risk Manag2008484785319066001
   PubMedGoogle Scholar
• BarriosVEscobarCde la FigueraMHigh doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE studyInt J Clin Pract20086272372818355238
   PubMed Web of Science ®Google Scholar
• DahlofBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet2002359995100311937178
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJBoschJDaviesRDagenaisGEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med200034214515310639539
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med200134586186911565518
   PubMed Web of Science ®Google Scholar
• HallerHEffective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular riskInt J Clin Pract20086278179018355239
   PubMed Web of Science ®Google Scholar
• McClellanKJJarvisBLercanidipine: a review of its use in hypertensionDrugs2000601123114011129125
   PubMed Web of Science ®Google Scholar
• OteroMManidipine-delapril combination in the management of hypertensionVasc Health Risk Manag2007325526317703633
   PubMedGoogle Scholar
• BangLMChapmanTMGoaKLLercanidipine: a review of its efficacy in the management of hypertensionDrugs2003632449247214609358
   PubMed Web of Science ®Google Scholar
• MeredithPALercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivityExpert Opin Investig Drugs1999810431062
   PubMedGoogle Scholar
• EpsteinMLercanidipine: a novel dihydropyridine calcium-channel blockerHeart Dis2001339840711975824
   PubMedGoogle Scholar
• BarriosVNavarroAEsterasAAntihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE StudyBlood Press2002119510012035878
   PubMed Web of Science ®Google Scholar
• BarriosVEscobarCNavarroALercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA studyInt J Clin Pract2006601364137017073834
   PubMed Web of Science ®Google Scholar
• JamesIGJonesADaviesPA randomised, double-blind, doubledummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertensionJ Hum Hypertens20021660561012149668
   PubMed Web of Science ®Google Scholar
• LeonettiGMagnaniBPessinaACTolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensivesAm J Hypertens2002593294012441211
   PubMed Web of Science ®Google Scholar
• CherubiniAFabrisFFerrariEComparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) studyArch Gerontol Geriatr20033720321214511846
   PubMed Web of Science ®Google Scholar
• RomitoRPansiniMIPerticoneFComparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) StudyJ Clin Hypertens20035249253
   PubMedGoogle Scholar
• SomaMRNataliMDonettiEEffect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbitsBr J Pharmacol2003125147114769884075
   PubMed Web of Science ®Google Scholar
• RachmaniRLeviZZadokBSLosartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover studyClin Pharmacol Ther20027230230712235451
   PubMed Web of Science ®Google Scholar
• CanavesiMBaldiniNLeonardiAIn vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metal-loproteinases secretion by macrophagesJ Cardiovasc Pharmacol20044441642215454849
   PubMed Web of Science ®Google Scholar
• RoblesNROconJGomezCFLercanidipine in patients with chronic renal failure: the ZAFRA studyRen Fail200527738015717638
   PubMed Web of Science ®Google Scholar
• Dalla VestraMPozzaGMoscaAEffect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (Diabete, Ipertensione, Albuminuria, Lercanidipina)Diabetes Nutr Metab20041725926616295047
   PubMedGoogle Scholar
• VivianiGLLercanidipine in type II diabetic patients with mild to moderate arterial hypertensionJ Cardiovasc Pharmacol20024013313912072586
   PubMed Web of Science ®Google Scholar
• RoblesNRPastorLManjonMLercanidipine in diabetic patients with renal failureNefrologia20042433834315455493
   PubMed Web of Science ®Google Scholar
• AcanforaDGheorghiadeMTrojanoLA randomized, double-blind comparison of lercanidipine 10 and 20 mg in patients with stable effort angina: clinical evaluation of cardiac function by ambulatory ventricular scintigraphic monitoringAm J Ther20041142343215543081
   PubMed Web of Science ®Google Scholar
• HairPIScottLJPerryCMFixed-dose combination lercanidipine/ enalaprilDrugs2007679510617209666
   PubMed Web of Science ®Google Scholar
• ToddPAHeelRCEnalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failureDrugs1986311982483011386
   PubMed Web of Science ®Google Scholar
• ToddPAGoaKLEnalapril. A reappraisal of its pharmacology and therapeutic use in hypertensionDrugs1992433463811374319
   PubMed Web of Science ®Google Scholar
• RavidMBroshDLeviZUse of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trialAnn Intern Med19981289829889625684
   PubMed Web of Science ®Google Scholar
• HosomiNMizushigeKOhyamaHAngiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitusStroke2001321539154511441198
   PubMed Web of Science ®Google Scholar
• RoseiEARizzoniDMuiesanMLEffects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitusJ Hypertens20052343544415662233
   PubMed Web of Science ®Google Scholar
• MinaiKMatsumotoTHorieHBradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitorsJ Am Coll Cardiol2001371565157011345366
   PubMed Web of Science ®Google Scholar
• McInnesGTAntihypertensive drugs in combination: additive or greater than additive?J Hum Hypertens20072191491617700727
   PubMed Web of Science ®Google Scholar
• AndreadisEATsourousGIMarakomichelakisGEHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertensionJ Hum Hypertens20051949149615759025
   PubMed Web of Science ®Google Scholar
• GojanovicBFeihlFLiaudetLConcomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertensionJ Renin Angiotensin Aldosterone Syst200891918404602
   PubMed Web of Science ®Google Scholar
• MesserliFHVasodilatory edema: a common side effect of antihypertensive therapyCurr Cardiol Rep2002447948212379167
   PubMedGoogle Scholar
• NeutelJMSmithDHWeberMASchofieldLPurkayasthaDGatlinMEfficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) studyJ Clin Hypertens20057641646
   PubMedGoogle Scholar
• MugelliniAVaccarellaACelentanoAScanferlaFZoppiAFogariRFixed combination of manidipine and delapril in the treatment of mild to moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoringBlood Press Suppl2005161316060411
   PubMedGoogle Scholar
• AmarJVaurLPerretMBailleauCEtienneSChamontinBHypertension in high-risk patients: beware of the underuse of effective combination therapy (results of the PRATIK study)J Hypertens20022077978411910316
   PubMed Web of Science ®Google Scholar
• StaessenJAFagardRThijsLRandomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial InvestigatorsLancet19973507577649297994
   PubMed Web of Science ®Google Scholar
• LiuLWangJGGongLLiuGStaessenJAComparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative GroupJ Hypertens199816182318299869017
   PubMed Web of Science ®Google Scholar
• DahlofBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet200536689590616154016
   PubMed Web of Science ®Google Scholar
• JamersonKWeberABakrisGLBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patientsN Engl J Med20083592417242819052124
   PubMed Web of Science ®Google Scholar
• AgrawalRMarxAHallerHEfficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertensionJ Hypertens20062418519216331117
   PubMed Web of Science ®Google Scholar
• Data on fileEfficacy and tolerability of a combination of lercanidipine and enalapril in patients with mild to moderate essential hypertension not adequately controlled by enalapril treatment (add-on to enalapril) [CLP1-0019]Milan, ItalyRecordati Sp2004
   Google Scholar
• Data on fileEfficacy and tolerability of a combination of lercanidipine and enalapril in patients with mild to moderate essential hypertension not adequately controlled by lercanidipine treatment (add-on to lercanidipine) [CLP1-0018]Milan, ItalyRecordati SpA2004
   Google Scholar
• PuigJGCalvoCLuurilaOLercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPMJ Hum Hypertens20072191792417581601
   PubMed Web of Science ®Google Scholar
• RumpLCEfficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertensionArzneimittelforschung20106012413020422943
   PubMed Web of Science ®Google Scholar
• BangaloreSKamalakkannanGParkarSMesserliFHFixed-dose combinations improve medication compliance: a meta-analysisAm J Med200712071371917679131
   PubMed Web of Science ®Google Scholar
• WaeberBBurnierMBrunnerHRCompliance with antihypertensive therapyClin Exp Hypertens19992197398510423118
   PubMed Web of Science ®Google Scholar
• ManciaGGrassiGZanchettiANew-onset diabetes and antihypertensive drugsJ Hypertens20062431016331092
   PubMed Web of Science ®Google Scholar
• Gil GuillénVAbellanJLlisterriJLEfficacy and safety of lercanidipine in combination with enalapril in HBP: preliminary results of ZANYCONTROL study group [Abstract]Am J Hypertens200316115A
   Web of Science ®Google Scholar